Kamada Ltd.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. The company's products include KAMRAB/KEDRAB for rabies prevention, CYTOGAM for preventing Cytomegalovirus disease in various organ transplants, VARIZIG for post-exposure chickenpox prevention, WINRHO SDF for immune thrombocytopenic purpura and rhesus isoimmunization suppression, HEPAGAM B for preventing hepatitis B recurrence in liver transplants and post-exposure prophylaxis, GLASSIA for intravenous AATD, KAMRHO (D) IM for preventing hemolytic disease of newborns, and Echis coloratus and Vipera palaestinae Antiserum to treat snake bites. Kamada Ltd. also distributes biopharmaceutical products in Israel. These include BRAMITOB for chronic pulmonary infection, FOSTER for asthma, TRIMBOW for chronic obstructive pulmonary disease, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, AEROBIKA (an OPEP device), RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria, SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis, IVIG for various immunodeficiency-related conditions, VARITECT for chickenpox and zoster herpes, ZUTECTRA and HEPATECT CP for preventing hepatitis B, MEGALOTECT CP for CMV virus, RUCONEST for angioedema attacks, HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events, ALBUMIN and ALBUMIN for blood plasma, Factor VIII for hemophilia type A, and Factor IX for hemophilia type B. Additionally, the company distributes COAGADEX for hereditary factor X deficiency, IXIARO for Japanese encephalitis, VIVOTIF for salmonella typhi, PROCYSBI for nephropathic cystinosis, LAMZEDE for alpha-mannosidosis, RYPLAZIM for hypoplasminogenemia, ELIGARD for prostate cancer, and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.